Analyst Ratings For Cara Therapeutics
Portfolio Pulse from Benzinga Insights
Cara Therapeutics (NASDAQ:CARA) has received mixed analyst ratings over the past three months, with a total of 4 bullish ratings. The 12-month price targets show an average of $4.62, with a high of $6.00 and a low of $2.50, marking a significant decline from the previous average. The company's financial performance indicates challenges in revenue growth and efficiency, with a notable revenue decline of -55.0% as of September 30, 2023, and below-average ROE and ROA. However, it maintains a strong net margin and a prudent debt management strategy.
March 05, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cara Therapeutics has received mixed but predominantly bullish analyst ratings, with a notable decline in the average price target. Financial challenges are evident in revenue growth and efficiency metrics, but the company maintains a strong net margin and prudent debt management.
The mixed analyst ratings with a downward adjustment in price targets suggest uncertainty about Cara Therapeutics' short-term stock performance. The financial challenges, particularly in revenue growth, could dampen investor sentiment. However, the strong net margin and low debt levels might mitigate negative perceptions, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100